REGENXBIO Inc.

Listed Company

RGNXCIK 0001590877NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)FY ends Dec 31

Period

FY 2025

Revenue

$170.44M

Net Income

$-193.88M

Total Assets

$453.03M

Equity

$102.73M

Shares Out

51.61M

Op. Cash Flow

$-123.96M

Business

REGENXBIO Inc. is a clinical-stage biotechnology company that develops adeno-associated virus (AAV) vector-based gene therapies using its proprietary NAV® Technology Platform. It offers investigational and commercial AAV Therapeutics, including retinal, neuromuscular and neurodegenerative candidates (for example ABBV‑RGX‑314, RGX‑202, RGX‑121 and RGX‑111), as well as delivery devices, manufacturing platforms (NAVXpress®) and analytical services. The company operates integrated research and development, clinical development and manufacturing capabilities and sublicensing/collaboration activities. Its products and programs are advanced through global clinical trials and commercial collaborations, partnerships and CDMO channels.

Summary from filing dated 2025-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	170	83	90	113	470
Cost of license and royalty revenues	20	34	—	—	—
Research and development	228	209	232	242	181
General and administrative	83	77	88	85	79
Credit losses (recoveries)	—	−5	0	0	−3
Impairment of long-lived assets	—	2	—	—	—
Other operating expenses	179,000	865,000	397,000	−7	333,000
Total operating expenses	332	317	358	376	310
Loss from operations	−161	−233	−268	−263	160
Interest income from licensing	83,000	174,000	25,000	342,000	719,000
Investment income	12	19	11	5	7
Interest expense	−45	−13	−7	−23	—
Total other income (expense)	−33	6	4	−18	−19
Net loss	−194	−227	−263	−280	128
Unrealized gain on available-for-sale securities, net	54,000	4	11	−13	−2
Total other comprehensive income	54,000	4	11	−13	−2
Comprehensive loss	−194	−223	−253	−293	126
Net loss per share, basic	−3.76	−4.59	−6.02	−6.5	3.01
Net loss per share, diluted	−3.76	−4.59	−6.02	−6.5	2.91
Weighted-average common shares outstanding, basic	52	50	44	43	42
Weighted-average common shares outstanding, diluted	52	50	44	43	44

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	34	58	35	97	345
Marketable securities	196	177	241	268	112
Accounts receivable	26	20	25	28	32
Prepaid expenses	12	9	15	14	19
Other current assets	13	14	20	9	10
Total current assets	281	278	335	416	519
Marketable securities	11	10	39	201	392
Accounts receivable	2	474,000	701,000	2	2
Property and equipment, net	105	118	132	142	132
Operating lease right-of-use assets	47	54	60	65	61
Restricted cash	2	2	2	2	2
Other assets	5	4	5	6	6
Total assets	453	466	574	833	1,114
Accounts payable	21	23	23	27	11
Accrued expenses and other current liabilities	38	38	50	47	76
Deferred revenue	10	115,000	148,000	2	3
Operating lease liabilities	8	8	7	6	2
Royalty monetization liabilities	40	34	—	—	—
Total current liabilities	118	103	130	130	130
Deferred revenue	19	—	—	—	—
Operating lease liabilities	65	74	82	89	85
Royalty monetization liabilities	147	25	—	—	—
Other liabilities	638,000	4	6	9	745,000
Total liabilities	350	206	262	317	350
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024	—	—	—	—	—
Common stock; $0.0001 par value; 100,000 shares authorized at December 31, 2025 and 2024; 50,892 and 49,549 shares issued and outstanding at December 31, 2025 and 2024, respectively	5,000	5,000	4,000	4,000	4,000
Additional paid-in capital	1,229	1,193	1,021	973	928
Accumulated other comprehensive loss	−687,000	−741,000	−4	−15	−3
Accumulated deficit	−1,130	−932	−705	−442	−161
Total stockholders equity	103	260	312	516	764
Total liabilities and stockholders equity	453	466	574	833	1,114

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−194	−227	−263	−280	128
Stock-based compensation expense	35	38	40	41	39
Depreciation and amortization	16	16	17	13	10
Net accretion of discounts on marketable debt securities	−5	−4	687,000	5	6
Net realized gain on investments	−62,000	−7	−2	79,000	−5
Impairment of long-lived assets	—	2	—	—	—
Non-cash interest expense	13	6	−414,000	137,000	5
Other non-cash adjustments	597,000	1	319,000	231,000	−281,000
Accounts receivable	−8	10	4	5	14
Prepaid expenses	−3	5	−620,000	5	−8
Other current assets	658,000	7	−11	247,000	−7
Operating lease right-of-use assets	7	6	6	4	5
Other assets	−613,000	807,000	2	31,000	−2
Accounts payable	−2	−292,000	−3	19	−2
Accrued expenses and other current liabilities	229,000	−12	2	−26	30
Deferred revenue	29	−33,000	−2	−1	−899,000
Operating lease liabilities	−9	−8	−7	−544,000	12
Other liabilities	−3	−3	−3	8	289,000
Net cash used in operating activities	−124	−173	−218	−207	219
Purchases of marketable debt securities	−333	−190	−87	−185	−498
Maturities of marketable debt securities	319	290	285	203	170
Sales of equity securities	62,000	6	2	524,000	6
Purchases of property and equipment	−2	−2	−10	−31	−84
Net cash provided by (used in) investing activities	−16	103	191	−12	−407
Proceeds from exercise of stock options	300,000	2	2	3	4
Taxes paid related to net settlement of stock-based awards	−633,000	−910,000	−419,000	−284,000	−2,000
Proceeds from issuance of common stock under employee stock purchase plan	1	1	2	2	2
Proceeds from public offering of common stock and pre-funded warrants, net of issuance costs	—	131	—	—	—
Expenses related to at-the-market offering programs	−357,000	−323,000	—	—	—
Proceeds from issuance of royalty bond and warrants, net of transaction costs	144	—	—	—	—
Repayments under royalty monetization liabilities, net of interest	−28	−40	—	—	—
Net cash provided by financing activities	117	93	−35	−29	195
Net increase (decrease) in cash and cash equivalents and restricted cash	−23	23	−62	−248	7
Cash paid (received) for income taxes	285,000	−72,000	−142,000	12	6
Cash paid for interest under royalty monetization liabilities	32	7	—	—	—
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	889,000	339,000	—	—	558,000
Deferred equity offering costs in accounts payable and accrued expenses and other current liabilities	153,000	222,000	—	—	—
Deferred equity offering costs reclassified	499,000	628,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro